CrossRef Immunopathogenic mechanisms and immunoregulatory therapies in MASLD Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A
In 1997, the FDA withdrew fenfluramine, unleashing one of the largest pharmaceutical liability cases in history
#AddictionMedicine #GLP1 #RecoveryScience #PublicHealth #CaronTreatmentCenters #CASPR #SteveKleinMD To view or add a comment, sign in American Osteopathic Academy of Addiction Medicine - AOAAM and Opioid Response Network Fall 2025 Presentation Examining the Severity and Progression of Illicitly Manufactured Fentanyl Withdrawal: A Quasi-experimental Comparison Presented by: Anjalee Sharma, PhD Assistant Research Scientist at Friends Research Institute, Baltimore, MD As illicitly manufactured fentanyl has largely replaced heroin in the U.S., its withdrawal characteristics remain insufficiently understood
Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: a systematic review and meta-analysis
But its well-studied and has proven long-term safety